The factors affecting firms' growth: investment in tangible versus intangible assets in the Greek pharmaceutical industry Online publication date: Sat, 24-May-2008
by Ilias A. Makris
International Journal of Behavioural and Healthcare Research (IJBHR), Vol. 1, No. 1, 2008
Abstract: The present paper examines the factors that result in firms' good performance with a focus on the pharmaceutical industry, which constitutes an important part of the economy. An econometric analysis revealed that the investment in intangible assets (mainly in innovative activity) contributes more to the gross sales and employment growth than the investment in tangible assets. Furthermore, through the segregation of the innovative process to in-house Research and Development (R&D), production in third-party facilities and the acquisition of intellectual property rights, we found that only the former seems to have a positive effect on firm growth. Real innovative activity appears to be a critical issue in the survival and success of the pharmaceutical firms as opposed to the other kinds of investment or ownership status (subsidiary versus domestic). The results strongly indicate that firms in the sector (especially those that are independent) should focus on in-house innovative activity as a central issue of future strategies.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Behavioural and Healthcare Research (IJBHR):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com